The European Medicines Agency's use of prioritised independent research for best evidence in regulatory action on diclofenac.

Arlett, Peter; Sarac, Sinan B; Thomson, Andrew; Davies, Claire; Teixeira, Tania; Blake, Kevin V; Stenver, Doris

Arlett, Peter; Sarac, Sinan B; Thomson, Andrew; Davies, Claire; Teixeira, Tania; Blake, Kevin V; Stenver, Doris.

Affiliation

Arlett P; European Medicines Agency, London, UK.

Pharmacoepidemiol Drug Saf ; 23(4): 431-4, 2014 Apr.

Article in En | MEDLINE | ID: mdl-24616204

Subject(s)

Diclofenac/adverse effects; Drug and Narcotic Control/legislation & jurisprudence; Pharmacovigilance; Anti-Inflammatory Agents, Non-Steroidal/adverse effects; Decision Making; European Union; Humans; Research/organization & administration; Risk Assessment

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Diclofenac / Drug and Narcotic Control / Pharmacovigilance Type of study: Etiology_studies / Risk_factors_studies Limits: Humans Language: En Journal: Pharmacoepidemiol Drug Saf Journal subject: EPIDEMIOLOGIA / TERAPIA POR MEDICAMENTOS Year: 2014 Document type: Article Country of publication: United kingdom

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google